ATTD 2026: Diabetes Congres

Dr. Juan Pablo Frías, Medical Director and Principal Investigator at the Los Angeles Institute for Metabolic Research, presented 52-week data of icovamenib in people with type 2 diabetes at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona, Spain.

Dr. Frías was an invited speaker at the 1st ATTD Congress in Prague in 2008, where he presented on two therapies that were just emerging at the time—the first GLP-1 receptor agonist (exenatide twice daily) and the first amylin analog (pramlintide) for the treatment of diabetes.

From those early GLP-1 and amylin therapies to today’s next generation of metabolic treatments, the field has advanced tremendously.

Over the past two decades, investigators and staff now at Los Angeles Institute for Metabolic Research have contributed to the clinical development of many important therapies for diabetes, obesity, and metabolic liver disease—and we remain committed to continuing to help advance the field.